Evidence map›Paper›PMID 39441453›Full record

Trial reportInternational journal of clinical oncology2025

Influence of major hepatectomy on gemcitabine-based chemotherapy for recurrent biliary tract cancer after surgery: a subgroup analysis of JCOG1113.

Tatsuya Okuno, Chigusa Morizane, Junki Mizusawa, Hiroaki Yanagimoto, Satoshi Kobayashi, Hiroshi Imaoka, Takeshi Terashima, Hisato Kawakami, Yusuke Sano, Takuji Okusaka and 15 more

Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Tatsuya OkunoDepartment of Medical Oncology, Faculty of Medicine, Kindai University, Osakasayama City, 377-2, Ohno-Higashi, Osaka, 589-8511, Japan. t-okuno@pg7.so-net.ne.jp.ORCID http://orcid.org/0000-0002-5450-8841
Chigusa MorizaneDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Junki MizusawaJCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Hiroaki YanagimotoDepartment of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Satoshi KobayashiDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Hiroshi ImaokaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Takeshi TerashimaDepartment of Gastroenterology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.
Hisato KawakamiDepartment of Medical Oncology, Faculty of Medicine, Kindai University, Osakasayama City, 377-2, Ohno-Higashi, Osaka, 589-8511, Japan.
Yusuke SanoJCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Takuji OkusakaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Masafumi IkedaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Masato OzakaHepato-Biliary-Pancreatic Medicine Department, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Haruo MiwaGastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.
Akiko TodakaDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Satoshi ShimizuDepartment of Gastroenterology, Saitama Cancer Center, Saitama, Japan.
Nobumasa MizunoDepartment of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan.
Mitsugu SekimotoDepartment of Surgery, Kansai Medical University Hospital, Osaka, Japan.
Keiji SanoDepartment of Surgery, Teikyo University School of Medicine, Tokyo, Japan.
Kazutoshi TobimatsuDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Akio KatanumaCenter for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
Kunihito GotohDepartment of Surgery, NHO Osaka National Hospital, Osaka, Japan.
Hironori YamaguchiDepartment of Clinical Oncology, Jichi Medical University, Tochigi, Japan.
Hiroshi IshiiClinical Research Center, Chiba Cancer Center, Chiba, Japan.
Junji FuruseDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Makoto UenoDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMajor hepatectomy (MH) can increase the risk of adverse events (AEs) owing to impaired drug metabolism due to decreased liver volume and surgical injury. Thus, we performed this subgroup analysis using data from JCOG1113, a phase III trial comparing gemcitabine plus S-1 (GS) and gemcitabine plus cisplatin (GC) in patients with advanced and recurrent biliary tract cancer (BTC), to evaluate the effect of MH on the safety and efficacy of GC and GS regimens in patients with recurrent BTC.

methodsOf the 354 patients with advanced BTC enrolled in JCOG1113, 76 patients with postoperative recurrence (30 in the MH group and 46 in the non-MH group) were analyzed.

resultsGrade ≥ 3 platelet count decreased in both arms was more frequent in the MH group than in non-MH group (GC, 0.0 vs. 17.6%; GS, 3.9 vs. 15.4%). However, in the MH group, the white blood cell decreased (GC, 55.0 vs. 38.5%; GS, 23.1 vs. 7.7%) and anemia (GC, 15.0 vs. 11.8%; GS, 23.1 vs. 7.7%) were less common than in the non-MH group. The MH and non-MH groups showed no significant difference in overall survival (OS) in both GC [median OS, 23.0 in MH vs. 16.9 months in non-MH (hazard ratio, 0.857; 95% CI 0.387-1.899)], and GS [median OS, 21.5 vs. 14.9 months (hazard ratio, 0.670; 95% CI 0.310-1.447)] arms.

conclusionsThe safety and efficacy of gemcitabine-based chemotherapy were comparable between patients who underwent MH and those who underwent other surgeries.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiliary Tract NeoplasmsDeoxycytidineGemcitabineHepatectomyNeoplasm Recurrence, LocalTegafurAdultAgedCisplatinDrug CombinationsFemaleHumansMaleMiddle AgedOxonic AcidCisplatinDeoxycytidineDrug CombinationsGemcitabineOxonic AcidS 1 (combination)TegafurBiliary tract cancersChemotherapyMajor hepatectomy

Identifiers

PMID39441453

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.